PT - JOURNAL ARTICLE AU - Müller, Frank AU - Hansen, Alexis AU - Kube, Megan AU - Arnetz, Judith E. AU - Alshaarawy, Omayma AU - Achtyes, Eric D. AU - Holman, Harland T. TI - Translation, cultural adaption, and validation of the PHQ-9 and GAD-7 in Kinyarwanda for primary care in the United States AID - 10.1101/2024.04.18.24306010 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.18.24306010 4099 - http://medrxiv.org/content/early/2024/04/19/2024.04.18.24306010.short 4100 - http://medrxiv.org/content/early/2024/04/19/2024.04.18.24306010.full AB - Background Depression and anxiety are significant health burdens that greatly impact the quality of life of refugees and migrants. In this study, we have translated and culturally adapted the Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder Screener (GAD-7) into Kinyarwanda and performed a validation study in a United States (US) primary care setting.Methods A committee of experts translated and culturally adapted the PHQ-9 and GAD-7, incorporating feedback from cognitive interviews with bilingual participants. The translated instruments were then tested in a cross-sectional validation study. Analyses include internal consistency, discriminative validity, principal component analyses, and confirmatory factor analyses.Results Analyses of 119 responses indicated overall good internal consistency with Cronbach’s α of 0.85 (PHQ-9) and 0.92 (GAD-7). Both scales showed acceptable factor loadings between 0.44 and 0.90 in the principal component analyses and showed strong correlations with health-related quality of life and depression/anxiety symptoms measured with visual analog scales. Significantly higher scores for PHQ-9 and GAD-7 were shown among participants with known psychiatric conditions.Discussion PHQ-9 and GAD-7 demonstrated commendable applicability for Kinyarwanda-speaking patients in primary healthcare settings in the US. Culturally adapted translations of these tools may aid in mitigating health disparities among refugee and migrant populations. Future research should further validate these tools against gold-standard diagnostics in larger, geographically diverse samples.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received approval from the Corewell Health Institutional Review Board (Approval #: 2022-075). Only anonymized data were collected. Participants received written information and provided written consent prior to enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.